Depletion of ATXN3 was sufficient to attenuate Akt phosphorylation and enhance the ability of histone deacetylase inhibitors (HDACi) to induce PTEN expression and decrease cell viability, suggesting ATXN3 inhibition may be of therapeutic benefit in cancers with nongenetic inactivation of PTEN. The gene discussed is PTEN; the disease is cancer.